Survivin is a therapeutic target in Merkel cell carcinoma

Science Translational Medicine

Volumn 4, Issue 133, 2012, Pages

  Arora, Reety ^a   Shuda, Masahiro ^a   Guastafierro, Anna ^a   Feng, Huichen ^a   Toptan, Tuna ^a   Tolstov, Yanis ^a   Normolle, Daniel ^a   Vollmer, Laura L ^b   Vogt, Andreas ^b,c   Dömling, Alexander ^b   Brodsky, Jeffrey L ^b   Chang, Yuan ^a   Moore, Patrick S ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; ANTINEOPLASTIC AGENT; BORTEZOMIB; CALMIDAZOLIUM; CASPASE 3; CASPASE 9; CHELERYTHRINE; CYCLIN E; DAUNORUBICIN; DISULFIRAM; DOXORUBICIN; ELLIPTICINE; IODOCETAMIDE; MESSENGER RNA; MITOXANTRONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NSC 95397; ONCOPROTEIN; RETINOBLASTOMA PROTEIN; SANGUINARINE; SEPANTRONIUM BROMIDE; SURVIVIN; T ANTIGEN; TENIPOSIDE; TOPOTECAN; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTOME; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALRUBICIN; VIRUS PROTEIN; BIRC5 PROTEIN, HUMAN; BORONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE; INHIBITOR OF APOPTOSIS PROTEIN; NAPHTHOQUINONE; PYRAZINE DERIVATIVE; RNA; VIRUS T ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIRC5A GENE; CANCER INHIBITION; CANCER SURVIVAL; CELL DEATH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DRUG POTENCY; DRUG RESISTANCE; DRUG SCREENING; DRUG TARGETING; DRUG TOLERABILITY; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; M PHASE CELL CYCLE CHECKPOINT; MERKEL CELL TUMOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT COURSE THERAPY; TRANSCRIPTION REGULATION; TUMOR VOLUME; ANIMAL; DRUG ANTAGONISM; GENE EXPRESSION PROFILING; GENETICS; MERKEL CELL POLYOMAVIRUS; METABOLISM; MOUSE MUTANT; NONOBESE DIABETIC MOUSE; NUCLEOTIDE SEQUENCE; PATHOGENICITY; POLYOMAVIRUS INFECTION; TRANSLATIONAL RESEARCH; TUMOR CELL LINE; VIROLOGY; VIRUS INFECTION;

ANIMALS; ANTIGENS, VIRAL, TUMOR; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; BORONIC ACIDS; CARCINOMA, MERKEL CELL; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMIDAZOLES; INHIBITOR OF APOPTOSIS PROTEINS; MERKEL CELL POLYOMAVIRUS; MICE; MICE, INBRED NOD; MICE, SCID; NAPHTHOQUINONES; POLYOMAVIRUS INFECTIONS; PYRAZINES; RNA, MESSENGER; RNA, NEOPLASM; TRANSLATIONAL MEDICAL RESEARCH; TUMOR VIRUS INFECTIONS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84860913780     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3003713     Document Type: Article

References (59)

1. P. J. Allen, W. B. Bowne, D. P. Jaques, M. F. Brennan, K. Busam, D. G. Coit, Merkel cell carcinoma: Prognosis and treatment of patients from a single institution. J. Clin. Oncol. 23, 2300-2309 (2005).
2. M. Veness, M. Foote, V. Gebski, M. Poulsen, The role of radiotherapy alone in patients with Merkel cell carcinoma: Reporting the Australian experience of 43 patients. Int. J. Radiat. Oncol. Biol. Phys. 78, 703-709 (2010).
3. T. Y. Eng, M. G. Boersma, C. D. Fuller, V. Goytia, W. E. Jones III, M. Joyner, D. D. Nguyen, A comprehensive review of the treatment of Merkel cell carcinoma. Am. J. Clin. Oncol. 30, 624-636 (2007).
4. B. Lemos, P. Nghiem, Merkel cell carcinoma: More deaths but still no pathway to blame. J. Invest. Dermatol. 127, 2100-2103 (2007).
5. N. C. Hodgson, Merkel cell carcinoma: Changing incidence trends. J. Surg. Oncol. 89, 1-4 (2005).
6. M. Agelli, L. X. Clegg, Epidemiology of primary Merkel cell carcinoma in the United States. J. Am. Acad. Dermatol. 49, 832-841 (2003).
7. J. Albores-Saavedra, K. Batich, F. Chable-Montero, N. Sagy, A. M. Schwartz, D. E. Henson, Merkel cell carcinoma demographics, morphology, and survival based on 3870 cases: A population based study. J. Cutan. Pathol. 37, 20-27 (2010).
8. M. Heath, N. Jaimes, B. Lemos, A. Mostaghimi, L. C. Wang, P. F. Peñas, P. Nghiem, Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: The AEIOU features. J. Am. Acad. Dermatol. 58, 375-381 (2008).
9. H. Feng, M. Shuda, Y. Chang, P. S. Moore, Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 319, 1096-1100 (2008).
10. O. Gjoerup, Y. Chang, Update on human polyomaviruses and cancer. Adv. Cancer Res. 106, 1-51 (2010).
11. P. S. Moore, Y. Chang, Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nat. Rev. Cancer 10, 878-889 (2010).
12. R. M. Schowalter, D. V. Pastrana, K. A. Pumphrey, A. L. Moyer, C. B. Buck, Merkel cell polyomavirus and two previously unknown polyomaviruses are chronically shed from human skin. Cell Host Microbe 7, 509-515 (2010).
13. H. Feng, J. L. Taylor, P. V. Benos, R. Newton, K. Waddell, S. B. Lucas, Y. Chang, P. S. Moore, Human transcriptome subtraction by using short sequence tags to search for tumor viruses in conjunctival carcinoma. J. Virol. 81, 11332-11340 (2007).
14. Y. L. Tolstov, A. Knauer, J. G. Chen, T. W. Kensler, L. A. Kingsley, P. S. Moore, Y. Chang, Asymptomatic primary Merkel cell polyomavirus infection among adults. Emerg. Infect. Dis. 17, 1371-1380 (2011).
15. M. Shuda, R. Arora, H. J. Kwun, H. Feng, R. Sarid, M. T. Fernández-Figueras, Y. Tolstov, O. Gjoerup, M. M. Mansukhani, S. H. Swerdlow, P. M. Chaudhary, J. M. Kirkwood, M. A. Nalesnik, J. A. Kant, L. M. Weiss, P. S. Moore, Y. Chang, Human Merkel cell polyomavirus infection I. MCV T antigen expression in Merkel cell carcinoma, lymphoid tissues and lymphoid tumors. Int. J. Cancer 125, 1243-1249 (2009).
16. M. Shuda, H. Feng, H. J. Kwun, S. T. Rosen, O. Gjoerup, P. S. Moore, Y. Chang, T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirus. Proc. Natl. Acad. Sci. U.S.A. 105, 16272-16277 (2008).
17. S. Bhatia, O. Afanasiev, P. Nghiem, Immunobiology of Merkel cell carcinoma: Implications for immunotherapy of a polyomavirus-associated cancer. Curr. Oncol. Rep. 13, 488-497 (2011).
18. + T-cell responses identified in Merkel cell carcinomas and blood. Clin. Cancer Res. 17, 6671-6680 (2011).
19. K. G. Paulson, J. G. Iyer, A. R. Tegeder, R. Thibodeau, J. Schelter, S. Koba, D. Schrama, W. T. Simonson, B. D. Lemos, D. R. Byrd, D. M. Koelle, D. A. Galloway, J. H. Leonard, M. M. Madeleine, Z. B. Argenyi, M. L. Disis, J. C. Becker, M. A. Cleary, P. Nghiem, Transcriptome-wide studies of Merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. J. Clin. Oncol. 29, 1539-1546 (2011).
20. Y. Chang, P. S. Moore, Merkel cell carcinoma: A virus-induced human cancer. Annu. Rev. Pathol. 7, 123-144 (2012).
21. J. A. DeCaprio, J. W. Ludlow, J. Figge, J. Y. Shew, C. M. Huang, W. H. Lee, E. Marsilio, E. Paucha, D. M. Livingston, SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell 54, 275-283 (1988).
22. J. W. Ludlow, J. Shon, J. M. Pipas, D. M. Livingston, J. A. DeCaprio, The retinoblastoma susceptibility gene product undergoes cell cycle-dependent dephosphorylation and binding to and release from SV40 large T. Cell 60, 387-396 (1990).
23. K. Ohtani, J. DeGregori, J. R. Nevins, Regulation of the cyclin E gene by transcription factor E2F1. Proc. Natl. Acad. Sci. U.S.A. 92, 12146-12150 (1995).
24. D. I. Linzer, A. J. Levine, Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17, 43-52 (1979).
25. J. Y. Zhu, M. Abate, P. W. Rice, C. N. Cole, The ability of simian virus 40 large T antigen to immortalize primary mouse embryo fibroblasts cosegregates with its ability to bind to p53. J. Virol. 65, 6872-6880 (1991).
26. Y. Jiang, H. I. Saavedra, M. P. Holloway, G. Leone, R. A. Altura, Aberrant regulation of survivin by the RB/E2F family of proteins. J. Biol. Chem. 279, 40511-40520 (2004).
27. D. Raj, T. Liu, G. Samadashwily, F. Li, D. Grossman, Survivin repression by p53, Rb and E2F2 in normal human melanocytes. Carcinogenesis 29, 194-201 (2008).
28. M. Shuda, H. J. Kwun, H. Feng, Y. Chang, P. S. Moore, Human Merkel cell polyomavirus small T antigen is an oncoprotein targeting the 4E-BP1 translation regulator. J. Clin. Invest. 121, 3623-3634 (2011).
29. R. Houben, M. Shuda, R. Weinkam, D. Schrama, H. Feng, Y. Chang, P. S. Moore, J. C. Becker, Merkel cell polyomavirus-infected Merkel cell carcinoma cells require expression of viral T antigens. J. Virol. 84, 7064-7072 (2010).
30. T. Nakahara, M. Takeuchi, I. Kinoyama, T. Minematsu, K. Shirasuna, A. Matsuhisa, A. Kita, F. Tominaga, K. Yamanaka, M. Kudoh, M. Sasamata, YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res. 67, 8014-8021 (2007).
31. A. W. Tolcher, D. I. Quinn, A. Ferrari, F. Ahmann, G. Giaccone, T. Drake, A. Keating, J. S. de Bono, A phase II study of YM155, a novel small-molecule suppressor of survivin, in castrationresistant taxane-pretreated prostate cancer. Ann. Oncol. 23, 968-973 (2012).
32. M. Ashburner, C. A. Ball, J. A. Blake, D. Botstein, H. Butler, J. M. Cherry, A. P. Davis, K. Dolinski, S. S. Dwight, J. T. Eppig, M. A. Harris, D. P. Hill, L. Issel-Tarver, A. Kasarskis, S. Lewis, J. C. Matese, J. E. Richardson, M. Ringwald, G. M. Rubin, G. Sherlock, Gene Ontology: Tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 25, 25-29 (2000).
33. T. Iwasa, I. Okamoto, K. Takezawa, K. Yamanaka, T. Nakahara, A. Kita, H. Koutoku, M. Sasamata, E. Hatashita, Y. Yamada, K. Kuwata, M. Fukuoka, K. Nakagawa, Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs. Br. J. Cancer 103, 36-42 (2010).
34. S. P. Tu, X.H. Jiang, M. C. Lin, J. T. Cui, Y. Yang, C. T. Lum, B. Zou, Y. B. Zhu, S. H. Jiang, W. M. Wong, A. O. Chan, M. F. Yuen, S. K. Lam, H. F. Kung, B. C. Wong, Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer Res. 63, 7724-7732 (2003).
35. R. Zhang, L. Ma, M. Zheng, J. Ren, T. Wang, Y. Meng, J. Zhao, L. Jia, L. Yao, H. Han, K. Li, A. Yang, Survivin knockdown by short hairpin RNA abrogates the growth of human hepatocellular carcinoma xenografts in nude mice. Cancer Gene Ther. 17, 275-288 (2010).
36. D. J. Klionsky, A. M. Cuervo, P. O. Seglen, Methods for monitoring autophagy from yeast to human. Autophagy 3, 181-206 (2007).
37. C. M. Wright, S. P. Seguin, S. W. Fewell, H. Zhang, C. Ishwad, A. Vats, C. A. Lingwood, P. Wipf, E. Fanning, J. M. Pipas, J. L. Brodsky, Inhibition of simian virus 40 replication by targeting the molecular chaperone function and ATPase activity of T antigen. Virus Res. 141, 71-80 (2009).
38. S. P. Seguin, C. W. Evans, M. Nebane-Akah, S. McKellip, S. Ananthan, N. A. Tower, M. Sosa, L. Rasmussen, E. L. White, B. E. Maki, D. S. Matharu, J. E. Golden, J. Aubé, J. L. Brodsky, J. W. Noah, High-throughput screening identifies a bisphenol inhibitor of SV40 large T antigen ATPase activity. J. Biomol. Screen. 17, 194-203 (2012).
39. A. Czarna, B. Beck, S. Srivastava, G. M. Popowicz, S. Wolf, Y. Huang, M. Bista, T. A. Holak, A. Dömling, Robust generation of lead compounds for protein-protein interactions by computational and MCR chemistry: p53/Hdm2 antagonists. Angew. Chem. Int. Ed. Engl. 49, 5352-5356 (2010).
40. G. M. Popowicz, A. Czarna, S. Wolf, K. Wang, W. Wang, A. Dömling, T. A. Holak, Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery. Cell Cycle 9, 1104-1111 (2010).
41. G. Sarek, S. Kurki, J. Enbäck, G. Iotzova, J. Haas, P. Laakkonen, M. Laiho, P. M. Ojala, Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas. J. Clin. Invest. 117, 1019-1028 (2007).
42. C. E. Petre, S. H. Sin, D. P. Dittmer, Functional p53 signaling in Kaposi's sarcoma-associated herpesvirus lymphomas: Implications for therapy. J. Virol. 81, 1912-1922 (2007).
43. H. Einsele, Bortezomib. Recent Results Cancer Res. 184, 173-187 (2010).
44. R. LeBlanc, L. P. Catley, T. Hideshima, S. Lentzsch, C. S. Mitsiades, N. Mitsiades, D. Neuberg, O. Goloubeva, C. S. Pien, J. Adams, D. Gupta, P. G. Richardson, N. C. Munshi, K. C. Anderson, Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 62, 4996-5000 (2002).
45. T. Nakahara, A. Kita, K. Yamanaka, M. Mori, N. Amino, M. Takeuchi, F. Tominaga, I. Kinoyama, A. Matsuhisa, M. Kudou, M. Sasamata, Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models. Cancer Sci. 102, 614-621 (2011).
46. T. Nakahara, M. Takeuchi, I. Kinoyama, T. Minematsu, K. Shirasuna, A. Matsuhisa, A. Kita, F. Tominaga, K. Yamanaka, M. Kudoh, M. Sasamata, YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res. 67, 8014-8021 (2007).
47. G. Ambrosini, C. Adida, D. C. Altieri, A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 3, 917-921 (1997).
48. H. Takeuchi, D. L. Morton, D. Elashoff, D. S. Hoon, Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine. Int. J. Cancer 117, 1032-1038 (2005).
49. J. Kim, J. M. McNiff, Nuclear expression of survivin portends a poor prognosis in Merkel cell carcinoma. Mod. Pathol. 21, 764-769 (2008).
50. D. C. Altieri, Validating survivin as a cancer therapeutic target. Nat. Rev. Cancer 3, 46-54 (2003).
51. S. Piña-Oviedo, K. Urbanska, S. Radhakrishnan, T. Sweet, K. Reiss, K. Khalili, L. Del Valle, Effects of JC virus infection on anti-apoptotic protein survivin in progressive multifocal leukoencephalopathy. Am. J. Pathol. 170, 1291-1304 (2007).
52. G. Kroemer, B. Levine, Autophagic cell death: The story of a misnomer. Nat. Rev. Mol. Cell Biol. 9, 1004-1010 (2008).
53. A. N. Santhanam, E. Bindewald, V. K. Rajasekhar, O. Larsson, N. Sonenberg, N. H. Colburn, B. A. Shapiro, Role of 3′UTRs in the translation of mRNAs regulated by oncogenic eIF4E - A computational inference. PloS One 4, e4868 (2009).
54. S. G. Ronan, A. D. Green, A. Shilkaitis, T. S. Huang, T. K. Das Gupta, Merkel cell carcinoma: In vitro and in vivo characteristics of a new cell line. J. Am. Acad. Dermatol. 29, 715-722 (1993).
55. S. T. Rosen, V. E. Gould, H. R. Salwen, C. V. Herst, M. M. Le Beau, I. Lee, K. Bauer, R. J. Marder, R. Andersen, M. S. Kies, R. Moll, W. W. Franke, J. A. Radosevich, Establishment and characterization of a neuroendocrine skin carcinoma cell line. Lab. Invest. 56, 302-312 (1987).
56. H. Feng, H. J. Kwun, X. Liu, O. Gjoerup, D. B. Stolz, Y. Chang, P. S. Moore, Cellular and viral factors regulating Merkel cell polyomavirus replication. PLoS One 6, e22468 (2011).
57. R. Houben, D. Schrama, M. Alb, C. Pföhler, U. Trefzer, S. Ugurel, J. C. Becker, Comparable expression and phosphorylation of the retinoblastoma protein in Merkel cell polyoma virus positive and negative Merkel cell carcinoma. Int. J. Cancer 126, 796-798 (2010).
58. M. W. Pfaffl, A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29, e45 (2001).
59. L. Zhao, M. A. Morgan, L. A. Parsels, J. Maybaum, T. S. Lawrence, D. Normolle, Bayesian hierarchical changepoint methods in modeling the tumor growth profiles in xenograft experiments. Clin. Cancer Res. 17, 1057-1064 (2011).